Brigham and Women’s Hospital
Department of Medicine
Division of Pharmacoepidemiology & Pharmacoeconomics
1620 Tremont Street, Suite 3030,
Boston, MA 02120
Phone: 617-278-0936 | Fax: 617-278-0930
Ameet Sarpatwari is an Instructor in Medicine at Harvard Medical School, an Associate Epidemiologist at Brigham and Women’s Hospital, and Assistant Director of the Program On Regulation, Therapeutics, And Law (PORTAL) within the Division of Pharmacoepidemiology and Pharmacoeconomics. His research draws upon his interdisciplinary training as an epidemiologist and lawyer and focuses on the effects of laws and regulations on therapeutic development, approval, use, and related public health outcomes. Among other projects, he is currently examining the public health impact of risk evaluation and mitigation strategies, the comparative safety and effectiveness of authorized and non-authorized generics, and the effect of variation in state drug product selection laws on generic drug prescribing.
Dr. Sarpatwari completed his undergraduate studies at the University of Virginia, where he was a Jefferson Scholar. He studied epidemiology at the University of Cambridge, where his doctoral work centered on uncovering disease progression, treatment effectiveness, and co-morbid burden among adults patients with primary immune thrombocytopenia. He subsequently studied law at the University of Maryland as a John L. Thomas Leadership Scholar.
Dr. Sarpatwari is currently the Principal Investigator on a Greenwall Foundation Making a Difference in Real-World Bioethics Dilemmas grant and a Faculty Affiliate with the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and the Behavioral Insights Group at the Harvard Kennedy School. He teaches an annual course on Public Health Law at the Harvard T.H. Chan School of Public Health.
Selected Publications | Current PubMed Search Results
- Avorn J, Sarpatwari A, Kesselheim AS. Forbidden and permitted statements in evolution: rules in evolution. N Engl J Med 2015. [In press]
- Sarpatwari A, Avorn J, Kesselheim AS. Progress and hurdles for follow-on biologics. N Engl J Med 2015;372(25):2380-82.
- Sarpatwari A, Darrow JJ, Kesselheim AS. Expanded access to investigational drugs. N Engl J Med 2015;372(15):1473-74.
- Sarpatwari A, Choudhry NK, Avorn J, Kesselheim AS. Paying physicians to prescribe generic drug and follow-on biologics in the United States. PLoS Med 2015;12(3):e1001802.
- Darrow JJ, Sarpatwari A, Avorn J, Kesselheim AS. Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med 2015;372(3):279-86.
- Sarpatwari A, Franklin JM, Avorn J, Seeger JD, Landon JE, Kesselheim AS. Are risk evaluation and mitigation strategies associated with less off-label use of medications? The case of ITP. AClin Pharmacol Ther 2015;97(2):186-93.
- Sarpatwari A, Kesselheim AS, Malin B, Gagne JJ, Schneeweiss S. Ensuring patient privacy in data sharing for postapproval research. N Engl J Med 2014;371(17):1644-49.
- Sarpatwari A, Avorn J, Kesselheim AS. Using a drug-safety tool to prevent competition. N Engl J Med2014;370(16):1476-78.
- Sarpatwari A, Robertson CT, Yokum DV, Joiner K. Crowdsourcing public health experiments: a response to Jonathan Darrow’s “Crowdsourcing Clinical Trials”. Minnesota Law Rev 2014;98:101-20
- Sarpatwari A. Just say no: the case against the reclassification of buprenorphine. Univ Maryland Law J Race Religion Gender & Class 2012;12:377-95. [Recipient of the Joseph Bernstein Award for the most significant student piece of scholarly writing]
- Sarpatwari A, Bussel JB, Erqou S, et al. Single-nucleotide polymorphism analysis demonstrates a significant association of tumour necrosis factor-alpha (TNFA) with primary immune thrombocytopenia. Hematology 2011;16(4):243-48.
- Anzures-Cabrera J,*Sarpatwari A,* Higgins JPT.* Expressing findings from meta-analyses of continuous outcomes in terms of risks. Stat Med 2011;30(25):2967-85. [*Joint first authors]
- Sarpatwari A, Provan D, Erqou S, et al. Autologous 111In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: A report from the United Kingdom ITP Registry. Br J Haematol 2010;151(5):477-87.
- Sarpatwari A, Watson S, Erqou S, et al. Health-related lifestyle in adults and children with primary ITP. Br J Haematol 2010;151(2):189-91.
- Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia (ITP) in the United Kingdom General Practice Research Database. Haematologica 2010;95(7):1167-75.
- Sarpatwari A, Segal JB, Bussel JB, Stasi R, Osborn J. A case of rich fruit. Blood 2009;113(124):6260.
- Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009;113(6):1231-40.